Orchid Pharma insolvency case: NCLAT notice to Ingen Capital directors

Ingen's counsel had said this would not be possible without it receiving specified information and documents

Gavel, law,
BS Reporter
Last Updated : Mar 03 2019 | 11:43 PM IST
The National Company Law Appellate Tribunal (NCLAT) has directed Ingen Capital directors Umesh Bhatia and Harish Bhatia to reply in three weeks on why action should not be taken against them on not paying the Rs 1,000 crore as specified in the approved Resolution Plan for Orchid Pharma. The order on Friday from S J Mukhopadhaya, head of the NCLAT,  says if the ‘show cause reply’ is not filed within three weeks, the body might initiate contempt proceedings and possibly a bailable warrant of arrest. The Union ministry of corporate affairs was made a respondent in the matter. Ingen had approached the NCLAT with an appeal, assailing the order passed by the NCLT bench which directed to deposit a third of the Rs 1,000 crore payable to secured creditors. The appellate body had directed it to unconditionally agree to deposit at least Rs 1,000 crore with the NCLT registrar.

Ingen's counsel  had said this would not be possible without it receiving specified information and documents. On February 1, the NCLAT issued a show cause notice, stating Ingen was now putting pre-conditions when no such stipulation was made earlier.

Ingen had, in the procedures before the NCLT, sought to replace the appointed RP with another expert. It had alleged it was asking for only limited information from the RP to raise funds towards the debt component from JM Financial but it was not being provided this. Hence, it was unable to proceed as envisaged in the approved Resolution Plan. The NCLT had refused the plea.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story